Immuron (IMRN) Projected to Post Quarterly Earnings on Friday

Immuron (NASDAQ:IMRN) is projected to post its results before the market opens on Friday, August 28th. Analysts expect Immuron to post earnings of ($0.0037) per share and revenue of $2.7450 million for the quarter.

Immuron Stock Performance

Shares of NASDAQ:IMRN opened at $1.14 on Wednesday. Immuron has a 1-year low of $0.68 and a 1-year high of $2.39. The business has a fifty day moving average price of $1.13 and a 200-day moving average price of $0.98.

Institutional Trading of Immuron

A hedge fund recently bought a new position in Immuron stock. Citadel Advisors LLC purchased a new stake in Immuron (NASDAQ:IMRN) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned approximately 0.29% of Immuron as of its most recent filing with the SEC. Institutional investors own 0.12% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Immuron in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Immuron Company Profile

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.